Press release

INITIAL RESULTS OF A STUDY, IN COLLABORATION WITH THE UCONN SCHOOL OF MEDICINE, HIGHLIGHT THE POTENTIAL OF IKONISYS' CELL-BASED DIAGNOSTIC PLATFORM IN IMMUNO-ONCOLOGY

- **New demonstration of Ikonisys technology's potential in immuno-oncology through its ability to detect rare cells in general and circulating tumor cells in particular**
- **Identification of 80 extremely rare antigen-specific CD8 T-Cells, in a background of over a million blood cells, through high-speed scanning with the Ikoniscope20 platform**
- **Antigen-specific T cells which play a central role in immunity to cancers and infectious agents through their capacity to kill malignant cells upon recognition by T-cell receptor**

Paris, September 6, 2021 – 5:45 PM CEST – Ikonisys SA (Code ISIN: FR00140048X2 / Mnémonique: ALIKO), a company specializing in the early and accurate detection of cancers with a unique fully-automated solution for medical analysis labs, announced the initial results of a study to demonstrate the capability of the Ikoniscope20 rare cell detection platform to enumerate specific populations of CD8 T cells. Such antigen-specific CD8 T cells are extremely rare, and are a perfect proof of demonstration of the ability to detect rare cells in general, and circulating tumor cells in particular. Antigen-specific T cells play a central role in immunity to cancers and infectious agents (such as viruses), through their capacity to kill malignant cells upon recognition by T-cell receptor of specific antigenic peptides presented on the surface of target cells. In this study, the two teams were able to identify about 80 antigen-specific T cells in a background of over a million blood cells by high-speed scanning for the presence of cells positive for fluorescently labelled MHC I-peptide complexes that bind to a T cell antigen-receptor. The study was carried out in collaboration with the Carole and Ray Neag Comprehensive Cancer Center of the University of Connecticut (UConn) School of Medicine.

Prof. Pramod K. Srivastava, Director of the Carole and Ray Neag Comprehensive Cancer Center (who also serves on the Board of ALIKO), commented, *"Detection and enumeration of cancer antigen-specific T cells in a reliable and reproducible manner is always challenging. These early results shall serve as a foundation of the use of this technology in monitoring immune responses to cancers in pre-clinical as well as clinical studies."*

Dr. Michael Kilpatrick, **Chief Scientific Officer of Ikonisys**, added, *"We are honored to be working with a leading medical center to demonstrate the potential of the Ikonisys platform in the detection and quantification of specific populations of clinically relevant cells in immuno-oncology. The study further validates the value of the Ikonisys platform for the detection and analysis of specific populations of*

rare cells present in complex specimens, an approach likely to have particular value in the current era of personalized and predictive medicine."

About Ikonisys

Ikonisys SA is a cell-based diagnostics company based in Paris (France), New Haven (Connecticut, USA) and Milan (Italy) specialized in the early and accurate detection of cancer. The company develops, produces and markets the proprietary Ikoniscope20® platform, a fully-automated solution designed to deliver accurate and reliable detection and analysis of rare and very rare cells. Ikonisys has received FDA clearance for several automated diagnostic applications, which are also marketed in Europe under CE certification. Through its breakthrough fluorescence microscopy platform, the company continues to develop a stream of new tests, including liquid biopsy tests based on Circulating Tumor Cells (CTC).

For further information, please go to www.Ikonisys.com

Contacts

Ikonisys
Alessandro Mauri
CFO
investors@ikonisys.com

NewCap
Olivier Bricaud / Louis-Victor Delouvrier
Investor Relations
Ikonisys@newcap.eu
Tel.: +33 (0)1 44 71 94 92

NewCap
Nicolas Merigeau
Media Relations
Ikonisys@newcap.eu
Tel.: +33 (0)1 44 71 94 98

Disclaimer

This press release contains forward-looking statements about the Company's prospects and development. These statements are sometimes identified by the use of the future tense, the conditional tense and forward-looking words such as "believe", "aim to", "expect", "intend", "estimate", "believe", "should", "could", "would" or "will" or, where appropriate, the negative of these terms or any other similar variants or expressions. This information is not historical data and should not be construed as a guarantee that the facts and data set forth will occur. This information is based on data, assumptions and estimates considered reasonable by the Company. It is subject to change or modification due to uncertainties relating to the economic, financial, competitive and regulatory environment. This information contains data relating to the Company's intentions, estimates and objectives concerning, in particular, the market, strategy, growth, results, financial situation and cash flow of the Company. The forward-looking information contained in this press release is made only as of the date of this press release. The Company does not undertake to update any forward-looking information contained in this press release, except as required by applicable law or regulation. The Company operates in a competitive and rapidly changing environment and therefore cannot anticipate all of the risks, uncertainties or other factors that may affect its business, their potential impact on its business or the extent to which the materialization of any one risk or combination of risks could cause results to differ materially from those expressed in any forward-looking information, it being recalled that none of this forward-looking information constitutes a guarantee of actual results.